Funding for this research was provided by:
National Heart, Lung, and Blood Institute (U01 HL089897, U01 HL089856)
Received: 26 February 2020
Accepted: 20 April 2020
First Online: 1 May 2020
Ethics approval and consent to participate
: Institutional review boards approved the COPDGene Study across the 21 US participating Clinical Centers between January 2008 and June 2011. All participants provided written informed consent.
: Not applicable.
: Dr. Occhipinti reports grants from Menarini Foundation, during the conduct of the study.Dr. Crapo reports grants from NIH/NHLBI, during the conduct of the study.Dr. Make reports funding from the NHLBI for the COPDGene study; grants and medical advisory boards from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Sunovian; personal fees for DSMB from Spiration and Shire/Baxalta; CME personal fees from WebMD, National Jewish Health, American College of Chest Physicians, Projects in Knowledge, Hybrid Communications, SPIRE Learning, Ultimate Medical Academy, Catamount Medical, Eastern Pulmonary Society, Catamount Medical Communications Medscape, Eastern VA Medical Center, Academy Continued Healthcare Learning, and Mt. Sinai Medical Center; royalites from Up-To-Date; medical advisory boards from Novartis, Phillips, Third Pole, Science 24/7, and Vernoa; grants from Pearl; outside the submitted work.Dr. Lynch reports grants from NHLBI, personal fees from Parexel, personal fees from Veracyte, personal fees from Boehringer Ingelheim, personal fees from Genentech/Roche, from Acceleron, outside the submitted work; In addition, Dr. Lynch has a patent SYSTEMS AND METHODS FOR CLASSIFYING SEVERITY OF COPD pending.Dr. Silverman reports grants from NIH, during the conduct of the study; grants and other from GlaxoSmithKline, outside the submitted work.Dr. Pistolesi reports grants and personal fees from Menarini, personal fees from MSD, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Zambon, personal fees from Grifols, personal fees from Menarini International, personal fees from Guidotti-Malesci, personal fees from CS Bering, non-financial support from VIDA Diagnostics, outside the submitted work.